European Biotechnology Magazine

European Biotechnology

1 / 4

The autumn issue of European Biotechnology magazine asks what happens when biotech leaves Earth. Our cover story explores how microgravity could help researchers study disease, improve drug formulations … more ➔

Get a free sample copy | Abo

2 / 4

The summer issue of European Biotechnology Magazine showcases the latest developments in drug delivery and RNA technologies. This issue features a list of eight venture capital firms to watch in 2026. … more ➔

Get a free sample copy | Abo

3 / 4

The Spring 2026 issue of European Biotechnology Magazine presents a list of start-ups to watch in 2026 and explores other fascinating topics such as: Can biotechnology finally fix infertility? Can … more ➔

Get a free sample copy | Abo

4 / 4

Europe is losing much of its expertise in deep tech and life sciences to the US. To prevent another generation of innovation from being lost, Europe must close the funding gaps. more ➔

Get a free sample copy | Abo

Stay up to date with the biotech industry!

Once a week, european-biotechnology.com brings you up to date on the latest developments in the biotech industry. In our free newsletter, you will find the latest news from business, research and politics, as well as lots of useful information and job vacancies.

Subscribe to our free newsletter!Subscribe here

licensing

Enodia lands $500M Pfizer deal to target proteins at the point of synthesis

Paris-based Enodia Therapeutics is entering a partnership with big pharma Pfizer to discover and develop small molecules for targeted protein degradation at the point of synthesis with a deal that could … more ➔

clinical data

Elicera’s CAR-T clears detectable lymphoma in eight patients

Swedish biotech Elicera Therapeutics reported complete metabolic responses in eight of 12 patients treated with its experimental CAR-T therapy ELC-301 in the Phase 1 portion of its CARMA trial. Six remained … more ➔

Sponsored Publications

1 / 5

autoimmune disease

AATec is pioneering a new approach to lung diseases

AATec is advancing ATL-105, a new recombinant version of alpha-1 antitrypsin for inhalation, into clinical development for chronic respiratory diseases. Rüdiger Jankowsky, CEO, and Gabriele Matschiner, … more ➔

2 / 5

Biosimilars

Perfusion for next generation biosimilars

Perfusion is here, and it is rewriting the rules of biologics and biosimilar manufacturing. What was once experimental has become industrial reality: scalable, robust, regulatorily accepted, and commercially … more ➔

3 / 5

CRO & CDMO

Every process is different. Not the platform.

For CDMOs, flexible upstream platforms can help streamline process development while maintaining reproducibility and continuity across scales. more ➔

4 / 5

Professor Jacob George, Chief Medical and Scientific Officer at the MHRA presenting his keynote speech at Phacilitate Advanced Therapies Europe, 2026

Cell & Gene Therapy

Europe’s CGT advantage at risk

Industry leaders at Advanced Therapies Europe 2026 warned that Europe must tackle barriers across commercialisation, regulation, reimbursement, manufacturing and patient access to retain its global … more ➔

5 / 5

Ponchi Kantt-Neaz, Global Executive Business Director 3PBIOVIAN

Commercial Strategy

3PBIOVIAN appoints Ponchi Kantt-Neaz as Global Executive Business Director

The appointment of Ponchi marking an important milestone in the company’s global commercial strategy and further strengthening its commercial leadership as the company continues to expand its presence … more ➔